FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

TANEN DAVID M 		2. Issuer Name and Ticker or Trading Symbol

Arno Therapeutics, Inc [ ARNI ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
Secretary
(Last)          (First)          (Middle)

200 ROUTE 31 NORTH, SUITE 104 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/3/2016
(Street)

FLEMINGTON, NJ 08822
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock                  362015   I   By Trust   (1)
Common Stock                  18691   I   By spouse for minor children   (2)
Common Stock   10/3/2016     P    142857   A   (3) 314569   D  
 

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $8.00                      (4) 9/29/2019   Common Stock   1250     1250   D  
 
Stock Option (right to buy)   $8.00                      (4) 11/5/2020   Common Stock   1250     1250   D  
 
Stock Option (right to buy)   $2.40                      (5) 11/4/2023   Common Stock   68448     68448   D  
 
Stock Option (right to buy)   $2.90                      (4) 1/24/2024   Common Stock   34224     34224   D  
 
Stock Option (right to buy)   $.37                      (6) 4/7/2026   Common Stock   88628     88628   D  
 
2016 Series F Warrants (right to buy)   $.4375   10/3/2016     P      71428       10/3/2016   10/3/2021   Common Stock   71428     (3) 71428   D  
 

Explanation of Responses:
( 1)  Held by the David M. Tanen Revocable Grantor Trust, of which the Reporting Person is a beneficiary.
( 2)  Held by the Reporting Person's spouse as custodian for the benefit of their minor children under the Uniform Gift to Minors Act. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
( 3)  The reported securities are included within 142,857 units of the Issuer's securities that the Reporting Person committed to purchase, at a per unit price of $0.35, pursuant to the Securities Purchase Agreement dated 8/15/16, a copy of which was filed as Exhibit 10.1 to the Issuer's Form 8-K filed 8/16/16.
( 4)  Currently exercisable.
( 5)  Vests in equal 36-monthly installments commencing 12/4/13.
( 6)  Vests in equal 12-monthly installments commencing 5/7/16.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
TANEN DAVID M
200 ROUTE 31 NORTH
SUITE 104
FLEMINGTON, NJ 08822 		X
Secretary

Signatures
/s/ David M. Tanen 10/5/2016
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Arno Therapeutics (CE) Charts.